Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification
Reexamination Certificate
2007-12-18
2007-12-18
Weber, Jon (Department: 1656)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
C530S350000, C530S359000
Reexamination Certificate
active
11220485
ABSTRACT:
The present invention provides methods and compositions for treating hypercholesterolemia using therapeutic apoE proteins. A therapeutic apoE protein is a naturally-occurring apoE protein (e.g., apoE1, apoE2, apoE2*, apoE2**, apoE3, and apoE4) that has one or more amino acid substitutions in the carboxy-terminal region which, when administered to a mammal having hypercholesterolemia, reduces the plasma cholesterol levels without inducing hypertriglyceridemia. The invention also provides a method for reducing plasma cholesterol using low doses of naturally-occurring apoE proteins.
REFERENCES:
patent: 5811243 (1998-09-01), Strittmatter et al.
patent: 5958684 (1999-09-01), Van Leeuwen et al.
patent: 6290949 (2001-09-01), French et al.
patent: 6756523 (2004-06-01), Kahn et al.
patent: 2002/0123093 (2002-09-01), Zannis et al.
patent: WO 96/14837 (1996-05-01), None
Zannis et al. “Mature human apolipoprotein E (apoE) isoprotein, apoE4” alignment result 1, SEQ ID No. 1, Database: A—Geneseq—8, Accession No. AAE13299.
Cardin et al., “Binding of a High Reactive Heparin to Human Apolipoprotein E: Identification of Two Heparin-Binding Domains,”Biochem. Biophys. Res. Commun. 134:783-789 (1986).
Chait et al., “Impaired Very Low Density Lipoprotein and Triglyceride Removal in Broad Beta Disease: Comparison With Endogenous Hypertriglyceridemia,”Metabolism27:1055-1066 (1978).
Chen et al., “Prolonged Correction of Hyperlipidemia in Mice With Familial Hypercholesterolemia Using an Adeno-Associated Viral Vector Expressing Very-Low Density Lipoprotein Receptor,”Molecular Therapy2:256-261 (2000).
Cladaras et al., “The Molecular Basis of a Familial apoE Deficiency. An Acceptor Splice Site Mutation in the Third Intron of the Deficient apoE Gene,”J. Biol. Chem. 262:2310-2315 (1987).
Cohn et al., “Plasma Concentration of Apolipoprotein E in Intermediate-Sized Remnant-Like Lipoproteins in Normolipidemic and Hyperlipidemic Subjects,”Arterioscler. Thromb. Vas. Biol. 16:149-159 (1996).
Cullen et al., “Phenotype-Dependent Differences in Apolipoprotein E Metabolism and in Cholesterol Homeostasis in Human Monocyte-Derived Macrophages,”J. Clin. Invest. 101:1670-1677 (1998).
Dong et al., “Human Apolipoprotein E: Role of Arginine 61 in Mediating the Lipoprotein Preferences of the E3 and E4 Isoforms,”J. Biol. Chem. 269:22358-22365 (1994).
Dong et al., “Novel Mechanism for Defective Receptor Binding of Apolipoprotein E2 in Type III Hyperlipoproteinemia,”Nature Struc. Biol. 3:718-722 (1996).
Ehnholm et al., “Role of Apolipoprotein E in the Lipolytic Conversion of β-Very Low Density Lipoproteins to Low Density Lipoproteins in Type III Hyperlipoproteinemia,”Proc. Natl. Acad. Sci. USA81:5566-5570 (1984).
Fan et al., “Increased Expression of Apolipoprotein E in Transgenic Rabbits Results in Reduced Levels of Very Low Density Lipoproteins and an Accumulation of Low Density Lipoproteins in Plasma,”J. Clin. Invest. 101:2151-2164 (1998).
Fazio et al., “Increased Atherosclerosis in Mice Reconstituted With Apolipoprotein E Null Macrophages,”Proc. Natl. Acad. Sci. USA94:4647-4652 (1997).
Fazio et al., “Altered Lipoprotein Metabolism in Transgenic Mice Expressing Low Levels of a Human Receptor-Binding-Defective Apolipoprotein E Variant,”J. Lipid Res. 35:408-416 (1994).
Fazio et al., “Susceptibility to Diet-Induced Atherosclerosis in Transgenic Mice Expressing a Dysfunctional Human Apolipoprotein E (Arg112, Cys142),”Arterioscler. Thromb. 14:1873-1879 (1994).
Gerritsen et al., “Hyperlipidemia in APOE2 Transgenic Mice is Ameliorated By a Truncated apoE Variant Lacking the C-Terminal Domain,”J. Lipid Research44:408-414 (2003).
Ghiselli et al., “Type III Hyperlipoproteinemia Associated With Apolipoprotein E Deficiency,”Science214:1239-1241 (1981).
Herz et al., “Lipoprotein and Receptor Interactions in vivo,”Curr. Opin. Lipidol. 6:97-103 (1995).
Huang et al., “Effects of Genotype and Diet on Cholesterol Efflux into Plasma and Lipoproteins of Normal, Apolipoprotein A-I-, and Apolipoprotein E-Deficient Mice,”Arterioscler. Thromb. Vasc. Biol. 17:2010-2019 (1997).
Huang et al., “A Plasma Lipoprotein Containing Only Apolipoprotein E and With γ Mobility on Electrophoresis Releases Cholesterol From Cells,”Proc. Natl. Acad. Sci. USA91:1834-1838 (1994).
Huang et al., “Apolipoprotein E2 Reduces the Low Density Lipoprotein Level in Transgenic Mice By Impairing Lipoprotein Lipase-Mediated Lipolysis of Triglyceride-Rich Lipoproteins,”J. Biol. Chem. 273:17483-17490 (1998).
Huang et al., “Overexpression and Accumulation of Apolipoprotein E as a Cause of Hypertriglyceridemia,”J. Biol. Chem. 273:26388-26393 (1998).
Huang et al., “Overexpression of Apolipoprotein E3 in Transgenic Rabbits Causes Combined Hyperlipidemia By Stimulating Hepatic VLDL Production and Impairing VLDL Lipolysis,”Arterioscler. Thromb. Vasc. Biol. 19:2952-2959 (1999).
Innerarity et al., “Enhanced Binding By Cultured Human Fibroblasts of apo-E-Containing Lipoproteins As Compared With Low Density Lipoproteins,”Biochemistry17:1440-1447 (1978).
Innerarity et al., “The Receptor-Binding Domain of Human Apolipoprotein E: Binding of Apolipoprotein E Fragments,”J. Biol. Chem. 258:12341-12347 (1983).
Ji et al., “Intravenous Heparinase Inhibits Remnant Lipoprotein Clearance From the Plasma and Uptake By the Liver:in vivo Role of Heparan Sulfate Proteoglycans,”J. Lipid Res. 36:583-592 (1995).
Ji et al.,“Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins By Cultured Cells,”J. Biol. Chem. 268:10160-10167 (1993).
Ji et al., “Secretion-Capture Role for Apolipoprotein E in Remnant Lipoprotein Metabolism Involving Cell Surface Heparan Sulfate Proteoglycans,”J. Biol. Chem. 269:2764-2772 (1994).
Ji et al., “Variable Heparan Sulfate Proteoglycan Binding of Apolipoprotein E Variants May Modulate the Expression of Type III Hyperlipoproteinemia,”J. Biol. Chem. 269:13421-13428 (1994).
Jong et al., “Nascent Very-Low-Density Lipoprotein Triacylglycerol Hydrolysis By Lipoprotein Lipase is Inhibited By Apolipoprotein E In a Dose-Dependent Manner,”Biochem. J. 328:745-750 (1997).
Kim D. et al., “Human Apolipoprotein E Receptor 2: A Novel Lipoprotein Receptor of the Low Density Lipoprotein Receptor Family Predominantly Expressed in Brain,”J. Biol. Chem. 271:8373-8380 (1996).
Kuipers et al., “Impaired Secretion of Very Low Density Lipoprotein-Triglycerides By Apolipoprotein E-Deficient Mouse Hepatocytes,”J. Clin. Invest. 100:2915-2922 (1997).
Kypreos et al., “Domains of Apolipoprotein E Contributing to Triglyceride and Cholesterol Homeostasis in Vivo,”J. Biol. Chem. 276:19778-19786 (2001).
Linton et al., “Prevention of Atherosclerosis in Apolipoprotein E-Deficient Mice by Bone Marrow Transplantation,”Science267:1034-1037 (1995).
Luo et al., “Structure and Expression of Dog Apolipoprotein A-1, E, and C-1 mRNAs: Implications for the Evolution and Functional Constraints of Apolipoprotein Structure,”J. Lipid Res. 30:1735-1746 (1989).
Mahley et al., “Apolipoprotein E: From Atherosclerosis to Alzheimer's Disease and Beyond,”Curr. Opin. Lipidol. 10:207-217 (1999).
Mahley et al., “Interaction of Plasma Lipoproteins Containing Apolipoproteins B and E With Heparin and Cell Surface Receptors,”Biochim. Biophys Acta575:81-91 (1979).
Mann et al., “Apolipoprotein E-1Harrisburg: A New Variant of Apolipoprotein E Dominantly Associated With Type III Hyperlipoproteinemia,”Biochim. Biophys. Acta1005:239-244 (1989).
Matsushima et al., “Primary Structure of Guinea Pig Apolipoprotein E,”Nucleic Acids Research18:202 (1989).
O
Kyriakos Kypreos E.
Zannis Vassilis I.
Clark Paul T.
Clark & Elbing LLP
KOS Pharmaceuticals, Inc.
Mitra Rita
The Trustees of Boston University
LandOfFree
Methods and compositions for treating hypercholesterolemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating hypercholesterolemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating hypercholesterolemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891686